Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/9512
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDemasi, M.-
dc.contributor.authorCaughey, G.-
dc.contributor.authorJames, M.-
dc.contributor.authorCleland, L.-
dc.date.issued2000-
dc.identifier.citationInflammation Research, 2000; 49(12):737-743-
dc.identifier.issn1023-3830-
dc.identifier.issn1420-908X-
dc.identifier.urihttp://hdl.handle.net/2440/9512-
dc.description.abstract<h4>Objective and design</h4>There is frequently poor correlation between in vitro methods for calculated cyclooxygenase (COX)-1/COX-2 selectivities of inflammatory agents. Therefore, we have examined the use of a single stimulus in a single cell type containing both COX isoforms, for determining the selectivities of COX-inhibitory agents.<h4>Methods</h4>Fresh human monocytes were stimulated with arachidonic acid (AA; 10 microM) for 15 min and prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) production were used as a measure of COX-1 activity. To measure COX-2 activity, cells were transiently pre-treated with aspirin to irreversibly inhibit constitutive COX-1, treated with lipopolysaccharide (LPS) to induce COX-2 and then stimulated with AA.<h4>Results</h4>Eicosanoid production in resting monocytes was predominantly COX-1 derived since it was not inhibited by NS-398 and also, COX-2 was not detectable. In LPS treated monocytes pre-treated transiently with aspirin, neither the level of induced COX-2 nor the activity was affected. Using the mean of the results for PGE2 and TXB2 inhibition, the COX-1/COX-2 ratios of the IC50 values for aspirin and NS-398 are < 0.1 and > 130, respectively.<h4>Conclusions</h4>This study has provided a system for investigating inhibition of COX isotypes without the potentially confounding effects of using different cell types with different stimuli for each isotype as seen in other published systems. Dose responses to aspirin and NS-398 which are COX- and COX-2 selective inhibitors respectively, confirmed the utility of this system.-
dc.description.statementofresponsibilityM. Demasi, G.E. Caughey, M.J. James, L.G. Cleland-
dc.language.isoen-
dc.publisherBirkhauser Verlag Ag-
dc.source.urihttp://dx.doi.org/10.1007/s000110050655-
dc.subjectMonocytes-
dc.subjectHumans-
dc.subjectSulfonamides-
dc.subjectAspirin-
dc.subjectNitrobenzenes-
dc.subjectIsoenzymes-
dc.subjectLipopolysaccharides-
dc.subjectEicosanoids-
dc.subjectDinoprostone-
dc.subjectThromboxane B2-
dc.subjectMembrane Proteins-
dc.subjectCyclooxygenase Inhibitors-
dc.subjectBlotting, Western-
dc.subjectCell Separation-
dc.subjectProstaglandin-Endoperoxide Synthases-
dc.subjectCyclooxygenase 1-
dc.subjectCyclooxygenase 2-
dc.subjectCyclooxygenase 2 Inhibitors-
dc.titleAssay of cyclooxygenase-1 and 2 in human monocytes-
dc.typeJournal article-
dc.identifier.doi10.1007/s000110050655-
pubs.publication-statusPublished-
dc.identifier.orcidCaughey, G. [0000-0003-1192-4121]-
dc.identifier.orcidJames, M. [0000-0002-4918-2998]-
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.